SCHEMBL3326248

SCHEMBL3326248

CCN(CC)CCNC(=O)c1ccc(S(N)(=O)=O)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.71
KMT2A Q03164 1/20 0.71
CA9 Q16790 5/20 0.70
CA12 O43570 4/20 0.70
ALDH1A1 P00352 3/20 0.69
LMNA P02545 2/20 0.69
MAPK1 P28482 2/20 0.69
SLC22A2 O15244 1/20 0.69
SLC22A1 O15245 1/20 0.69
TSHR P16473 1/20 0.69
ACHE P22303 1/20 0.69
CYP2C19 P33261 1/20 0.69
BLM P54132 2/20 0.68
PMP22 Q01453 1/20 0.68
CA2 P00918 11/20 0.64
CA1 P00915 10/20 0.64
GFER P55789 1/20 0.61
NFKB1 P19838 1/20 0.60
KCNH2 Q12809 1/20 0.60
CA14 Q9ULX7 2/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3326539 0.93 KDM4E (0.70) KDM4EKMT2ACA9CA12ALDH1A1
SCHEMBL3324262 0.92 CA2 (0.69) KDM4EKMT2ACA9CA12ALDH1A1
SCHEMBL3355609 0.91 CA2 (0.68) KDM4EKMT2ACA9CA12ALDH1A1
SCHEMBL3323540 0.90 KDM4E (0.74) KDM4EKMT2ACA9CA12ALDH1A1
SCHEMBL3357517 0.88 CA2 (0.71) KDM4EKMT2ACA9CA12ALDH1A1
SCHEMBL3322603 0.87 KDM4E (0.69) KDM4EKMT2ACA9CA12ALDH1A1
SCHEMBL3355307 0.85 CA2 (0.68) KDM4EKMT2ACA9CA12ALDH1A1
SCHEMBL3352783 0.85 CA2 (0.72) KDM4EKMT2ACA9CA12ALDH1A1
SCHEMBL3326602 0.85 CA2 (0.68) KDM4EKMT2ACA9CA12ALDH1A1
SCHEMBL3324700 0.85 KDM4E (0.70) KDM4EKMT2ACA9CA12ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2142499-B1 Substituted sulphonamides, process for their preparation, pharmaceutical composition comprising thereof and their use for treating glaucoma UNIMED PHARMA SPOL SRO (SK) 2014-12-10 EP claimed
US-8193184-B2 Substituted sulphonamides, process for their preparation, pharmaceutical composition comprising thereof and their use Unimed Pharma, SPOL, S.R.O. (SK) 2012-06-05 US claimed
US-20100125076-A1 SUBSTITUTED SULPHONAMIDES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITION COMPRISING THEREOF AND THEIR USE UNIMED PHARMA, SPOL. S R.O. (SK) 2010-05-20 US claimed
EP-2142499-A1 SUBSITUTED SULPHONAMIDES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITION COMPRISING THEREOF AND THEIR USE Unimed Pharma, Spol. S R.O. (SK) 2010-01-13 EP claimed
WO-2008130332-A1 SUBSITUTED SULPHONAMIDES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITION COMPRISING THEREOF AND THEIR USE UNIMED PHARMA, SPOL. S R.O. (SK) 2008-10-30 WO claimed
EP-2142499-B1 Substituted sulphonamides, process for their preparation, pharmaceutical composition comprising thereof and their use for treating glaucoma UNIMED PHARMA SPOL SRO (SK) 2014-12-10 EP disclosed
US-8193184-B2 Substituted sulphonamides, process for their preparation, pharmaceutical composition comprising thereof and their use Unimed Pharma, SPOL, S.R.O. (SK) 2012-06-05 US disclosed
US-20100125076-A1 SUBSTITUTED SULPHONAMIDES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITION COMPRISING THEREOF AND THEIR USE UNIMED PHARMA, SPOL. S R.O. (SK) 2010-05-20 US disclosed
EP-2142499-A1 SUBSITUTED SULPHONAMIDES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITION COMPRISING THEREOF AND THEIR USE Unimed Pharma, Spol. S R.O. (SK) 2010-01-13 EP disclosed
WO-2008130332-A1 SUBSITUTED SULPHONAMIDES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITION COMPRISING THEREOF AND THEIR USE UNIMED PHARMA, SPOL. S R.O. (SK) 2008-10-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100125076-A1 SUBSTITUTED SULPHONAMIDES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITION COMPRISING THEREOF AND THEIR USE ARSA, SMS, SULT1E1 KDM4E 438/4885KMT2A 1249/4885CA9 70/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.